Trial Profile
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Fluorouracil (Primary) ; Methotrexate (Primary) ; Pegfilgrastim (Primary)
- Indications Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.